fluoxetine

Ligand id: 203

Name: fluoxetine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: fluoxetine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 21.26
Molecular weight 309.13
XLogP 6.38
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Antidepressant of the selective serotonin uptake inhibitor class, used in the treatment of major depression and anxiety disorders. Additional indications include obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bulimia nervosa, panic disorder, body dysmorphic disorder, premenstrual dysphoric disorder (PMDD) and trichotillomania (compulsive hair pulling).
fluoxetine, along with amiloride and riluzole are repurposing candidates as potential therapeutics for secondary progressive multiple sclerosis (SPMS or late MS), having already been shown to provide neuroprotective benefit [1,4,7-8]. A Phase II clinical trial (NCT01910259, MS-SMART trial) is recruiting patients (April 2015).
Mechanism Of Action and Pharmacodynamic Effects
SSRIs are potent inhibitors of neuronal serotonin reuptake. By blocking sertonin reuptake, they increase serotonin stimulation of somatodendritic and terminal 5-HT1A receptors, and enhance serotonergic neurotransmission.